Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
Type:
Grant
Filed:
February 11, 2021
Date of Patent:
May 9, 2023
Assignees:
Assistance Publique—Hopitaux de Paris, Fondation Imagine—Institut des Maladies Génétiques, Université de Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)